<DOC>
	<DOCNO>NCT01793883</DOCNO>
	<brief_summary>This Phase 2 protocol design compare two dose level laninamivir octanoate versus placebo . The objective obtain safety efficacy adult age 18 64 year present clinic symptomatic presumptive influenza A B infection .</brief_summary>
	<brief_title>Efficacy Safety Study Laninamivir Octanoate TwinCaps® Dry Powder Inhaler Adults With Influenza</brief_title>
	<detailed_description>Approximately 636 subject randomize Study . Following confirmation circulate influenza local area , eligible subject recent onset symptomatic presumptive influenza A B infection enrol study . Subjects must randomize within 40 hour first symptom onset . Subjects randomize placebo , 40 80 mg laninamivir octanoate . The study conduct outpatient basis . The first dose study drug administer via inhalation within 4 hour randomization clinic , follow second dose home . Participants follow 14 day assess efficacy , virology safety . Outpatient visit investigational site schedule Days 2 ( optional PK Sub-study Visit ) 3 , 5 , 8 , 15 . An End study visit perform Day 29 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Main 1 . Provide write informed consent 2 . Males female age 1864 year , inclusive 3 . Symptomatic presumptive influenza A B infection define presence : 1. fever ≥38.0ºC ( ≥100.4 ºF ) screen visit OR history fever within 24 hour prior screen visit administer antipyretic ( ) 6 hour prior screen visit AND 2 . ≥1 moderate systemic symptom ( headache , feel feverish , body ache pain , fatigue ) AND 3 . ≥1 moderate respiratory symptom ( cough , sore throat nasal congestion ) 4 . Onset illness 40 hour prior randomization . Onset illness define time , first one following , occur : 1. time subject ' temperature measure elevate ( ≥38.0°C ( ≥100.4ºF ) OR 2. time subject first experience least one respiratory symptom ( cough , sore throat nasal congestion ) OR 3. time subject first experience least one systemic symptom ( headache , feel feverish , body ache pain , fatigue ) Main 1 . Use antiviral treatment influenza ( e.g . zanamivir , oseltamivir , rimantadine , amantadine ) within 14 day prior screen 2 . Received live attenuate trivalent inactivate influenza virus vaccine previous 3 week . 3 . History presence clinically significant pulmonary disease ( e.g. , chronic obstructive pulmonary disease , cystic fibrosis , bronchiectasis ) asthma 4 . History congestive heart failure symptom consistent New York Heart Association Class III IV functional status ( See Appendix A : ) within past 12 month 5 . Presence immune compromise status due chronic illness , organ transplantation use daily systemic immunosuppressant 6 . Presence clinically significant sign acute respiratory distress screen 7 . Current use inhaled medication ( nasal oral ) anticipate use inhaled medication ( nasal oral ) time study . 8 . Current history acute chronic renal impairment require hemodialysis and/or know calculated creatinine clearance ( CLCR ) &lt; 60 mL/min 9 . History presence clinical condition evidence organ dysfunction examination , opinion investigator , may affect either subject 's ability participate study study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Influenza Laninamivir Octanoate</keyword>
</DOC>